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Cysticneoplasmsofthepancreasareincreasinglyrecognizedduetothefrequentuseofabdominalimaging.Itisreportedthatupto
20% of abdominal cross-sectional scans identify incidental asymptomatic pancreatic cysts. Proper characterization of pancreatic
cystic neoplasms is important not only to recognize premalignant lesions that will require surgical resection, but also to allow
nonoperative management of many cystic lesions that will not require resection with its inherent morbidity. Though reliable
biomarkers are lacking, a wide spectrum of diagnostic modalities are available to evaluate pancreatic cystic neoplasms, including
radiologic, endoscopic, laboratory, and pathologic analysis. An interdisciplinary approach to management of these lesions which
incorporates recent, specialty-speciﬁc advances in the medical literature is herein suggested.
1.Introduction
With improvements in abdominal radiologic imaging, inci-
dental pancreatic cystic neoplasms are increasingly discov-
ered in as many as 20% of patients undergoing computed
tomography (CT) or magnetic resonance imaging (MRI) for
nonpancreatic indications. The proper management of these
l e s i o n si sc r i t i c a l[ 1–5].
The diﬀerential diagnoses for incidental pancreatic cystic
lesions include the following: (1) benign serous cystadenoma
or (2) premalignant mucinous cystic lesions, which are cate-
gorized into mucinous cystic neoplasm (MCN), branch duct
intraductal papillary mucinous neoplasm (BD-IPMN),main
duct IPMN (MD-IPMN), or mixed IPMN. Based on the
histologic type, pancreatic cystic neoplasms may have low or
high risk for malignant transformation.
Unfortunately, the imaging characteristics of pancreatic
cysts can be similar, making diﬀerentiation between benign
and premalignant conditions diﬃcult. In addition, current
cystﬂuidanalysistechniquesfailtoclearlydistinguishamong
the cysts. The deﬁnitive classiﬁcation of pancreatic cysts is
crucially important since precancerous lesions may require
surgical resection, while others that are benign or indolent
can be observed.
An interdisciplinary approach incorporating medical
pancreatology, therapeutic endoscopy, and pancreatic sur-
gery is critical to the evaluation of patients with cystic neo-
plasms of the pancreas. We provide a brief overview of the
clinical problem followed by interdisciplinary management
algorithms based on the current literature, including recent
guidelines from the major gastrointestinal and surgical
societies.
2.ClinicalandPathologic Features
Unlike most hepatic and renal cysts, pancreatic cystic lesions
raise clinical concern because of their potential for malig-
nancy and malignant transformation. About 50–60% of
pancreatic cystic lesions are cystic neoplasms, while cys-
tic degeneration of solid neoplasms represents 10%, and2 Gastroenterology Research and Practice
pseudocystsaccountforalmostone-thirdofpancreaticcystic
lesions. Nearly 90% of all pancreatic cystic neoplasms are
benign serous cystadenomas and premalignant or malig-
nant mucinous lesions, which include the parenchymal
MCN or intraductal papillary mucinous neoplasm (IPMN).
Appropriate management of these cystic neoplasms varies
considerably among the various types; a review of the salient
features of the most common lesions is outlined below
(Table 1)[ 6–16].
Serous cystadenomas (SCAs) are benign pancreatic cystic
neoplasms, which very rarely become malignant. They
account for over 30% of pancreatic cystic neoplasms and
arise anywhere in the pancreas. Some studies suggest higher
incidence of SCA in the body and tail of the pancreas, while
others favor the head and neck. SCA typically occurs in
women over the age of 60. The natural history of SCAs is
not well described; however, they appear to grow over time.
One study suggested that cysts smaller than 4cm expand
at a slower rate (0.12cm/year) than cysts larger than 4cm
(1.9cm/year). Malignant transformation is extremely rare
with only a few case reports of serous cystadenocarcinoma.
On pathologic examination, SCAs are lined characteristically
by glycogen containing cuboidal epithelial cells.
Mucinous cystic neoplasms (MCNs) are premalignant
parenchymal lesions that occur almost exclusively in women
between 40 and 50 years of age. They arise in the body
and tail of the pancreas in approximately 95% of patients
and are deﬁned by the presence of ovarian-like stroma on
pathology. Features concerning malignancy include older
age, large size (especially >6cm), and presence of thick cyst
wall, mural nodules, or peripheral eggshell calciﬁcation. The
true incidence of malignancy in MCNs is unknown although
recent studies suggest lower rates of invasive cancer (12–
29%) and carcinoma in situ (5.5%).
Intraductal papillary mucinous neoplasm (IPMN) is also
a mucinous cyst that arises from the pancreatic ductal epi-
thelium of the main duct, side branches, or both. It occurs
slightly more commonly in men between the ages of 50 and
60. While IPMNs usually arise in the head of the pancreas,
theycanoccuranywhereinthepancreasaswellasinmultiple
locations. There are 3 subtypes of IPMN: main duct (diﬀuse
or segmental involvement of the main duct, MD-IPMN),
branch duct (dilation of one or more side branches, BD-
IPMN), and mixed type (both main duct and side branch
involvement, mixed IPMN).
By pathology, IPMN may be classiﬁed as of gastric, intes-
tinal, or pancreaticobiliary type. There are variable reports in
themedicalliteratureontheclinicalsigniﬁcanceofhistologi-
cal grading, whether some types may be more indicative of
malignant potential. While histological grading may hold
some predictive accuracy, this is currently only achievable
postoperatively.
Accurate diﬀerentiation among the clinical subtypes is
important due to diﬀerences in malignant potential and
management. MD-IPMN is characterized by dilation of
the main pancreatic duct, usually due to a neoplasm in
the proximal duct producing mucus that ﬁlls and dilates
the entire duct, although it may also rarely result from
tumor involving the entire duct. About 40% of MD-IPMNs
contain malignancy at the time of diagnosis. Although main
pancreatic duct dilation greater than 15mm and presence
of mural nodules have been associated with malignancy,
malignancyisalsopresentinupto30%ofpatientswithMD-
IPMN without symptoms, mural nodules, or massive duct
dilation. Alternatively in another study, 35% of MD-IPMN
followed conservatively for a median of 48 months did not
develop malignancy.
Approximately 15% of BD-IPMN can undergo malig-
nant transformation. Ominous features suggesting progres-
sion in BD-IPMN include at least a 1cm increase in cyst
size, at least a 2mm increase in main pancreatic duct size,
or development of mural nodules over a median followup of
3.7 years, by one report. In this study, 32% of the patients
demonstrating progression of BD-IPMN underwent surgical
resection, and of these 31% were malignant.
Other less common pancreatic cystic neoplasms include
solid pseudopapillary neoplasm (SPEN), which occur almost
exclusively in young women. SPENs account for 1-2% of
pancreatic cystic neoplasms. They were ﬁrst described in
1959 as Frantz or Hamoudi tumors and were renamed
SPEN by the World Health Organization in 1996. Pathologic
examination reveals characteristic pseudopapillae with cystic
spaces containing hemorrhage and cholesterol clefts in myx-
oid stroma, alternating with solid tissue. SPENs may occur
anywhere throughout the pancreas. About 10–15% of SPENs
are malignant, and to date no predictors of aggressive
behavior have been identiﬁed. In addition, less commonly
observed lesions such as neuroendocrine or acinar cell
tumors can sometimes undergo cystic degeneration.
3.ImagingFeaturesandCystFluidAnalysis
Diﬀerentiating among pancreatic cystic lesions and predict-
ing malignant transformation can prove challenging. Cur-
rent evaluation of suspicious pancreatic cystic neoplasms
includes a combination of radiologic imaging, endoscopic
ultrasound (EUS), and cyst ﬂuid analyses. Overall, accurate
diagnosis of pancreatic cysts by radiologic imaging occurs in
about 40% to 60% of cystic lesions. CT and MRI both more
accurately predict the presence of malignancy in pancreatic
cysts (73% to 79%). These diagnostic rates are comparable
to EUS imaging. Commonly observed imaging features are
described below for the various cystic neoplasms [17–27].
Serous cystadenomas are typically multicystic with each
cyst<2cmand30%havealobular“honeycomb”appearance
due to dense septations producing multiple small cysts. Up
to 10% of SCAs may be unilocular or contain few septa
making diﬀerentiation from MCN diﬃcult. Occasionally
these lesions may appear solid due to the presence of numer-
ous microcysts that give the appearance of a homogeneous
hypoechoicmass.Thepathognomiccentralscaror“sunburst
calciﬁcation” is present in only about 30% of SCA (Figure 1).
Unlike SCA, MCNs usually appear as smooth, well-
deﬁned, and unilocular or with only a few septations
(Figure 2). Thick septae, mural nodules, and calciﬁcations
arefeaturesassociatedwithmalignancy.Calciﬁcationswithin
the peripheral wall of the cyst and occasionally within the
cyst occur in less than 20% of MCNs. Without a clear historyGastroenterology Research and Practice 3
Table 1: Characteristics of common pancreatic cysts.
Pseudocyst IPMN MCN SCA
Gender (male:female) 1:1 2:1 0.5:9.5 1:4
Age range (yr) 40–70 60–80 30–50 60–80
Imaging features
(i) Communication with main
duct Variable Yes No No
(ii) Location Any Head/uncinate—50% Body/tail—90% Variable
Cyst ﬂuid analysis
(i) Amylase High (>250U/L) High (>250U/L) Low (<250U/L) Low (<250U/L)
(ii) Mucin Low High High Low
(iii) CEA (elevated: >192ng/mL) Low Elevated Elevated Low
Malignant potential No Yes Yes No
Features suggestive of
malignancy None
Main duct > 10mm,
Branch duct: solid component,
mural nodule, cytology suspicious
or positive for malignancy
Larger than 6cm,
solid component,
mural nodule
None
Incidence of invasive cancer (%) 0 MD-IPMN: 40–50
BD-IPMN: 15 12 Very rare
Treatment
Observation
Resection if
symptomatic
Resection: MD-IPMN
Resection or surveillance:
BD-IPMN based on presence of
features suggestive of malignancy
and comorbid disease
Resection Resection if
symptomatic
Figure 1: Serous cystadenoma with central scar (arrow) on abdom-
inal CT.
Figure 2: Mucinous cystic neoplasm (arrow) on MRI abdomen.
ofacuteorchronicpancreatitis,diﬀerentiationofMCN,even
SCA and BD-IPMN, from pseudocysts may be diﬃcult by
imaging alone. Pseudocysts typically appear round or oval
with a thin, enhancing, possibly calciﬁed capsule on CT.
Communication with the pancreatic duct may or may not
be present.
IPMNs are ductal lesions involving the main pancre-
atic duct, side branches, or a combination of both. MD-
IPMNs lead to diﬀuse dilation of the main pancreatic duct
(Figure 3). Diagnosis of BD-IPMN is predicated on demon-
strating communication of the aﬀected side branch with the
main pancreatic duct (Figure 4). Approximately 20% of BD-
IPMNs diagnosed by radiology are actually mixed IPMNs by
pathology. Thisisclinicallyimportant becausemixedIPMNs
have a malignant potential similar to MD-IPMN, and, thus,
surgical resection is recommended for these lesions.
Imaging ﬁndings concerning malignancy in BD-IPMN
include main duct dilation greater than 10mm and presence
of a solid component or mural nodule. MRI identiﬁes solid
components, septa, main pancreatic duct dilation, commu-
nication with main pancreatic duct, and mural nodules with
similar sensitivity to EUS. Both have modest sensitivity for
detecting mural nodules (58% to 67%). Training in the
detection of 3 EUS criteria (hypoechoic lesion, smooth edge,
and hyperechoic rim) for mucus versus nodule improved
diagnostic accuracy from 57% to 79%.
Unlike most other pancreatic cystic lesions, SPENs and
cystic neuroendocrine tumors typically have characteristic
ﬁndings on imaging. The rare SPEN usually presents as a
large, well-deﬁned, encapsulated mass with peripheral solid
component and cystic degeneration in the center with areas4 Gastroenterology Research and Practice
Figure 3:MD-IPMNwithdiﬀuselydilatedmainpancreaticducton
MRCP (magnetic resonance cholangiopancreatography).
Figure 4: BD-IPMN with 2 cysts (arrows) communicating with
nondilated main pancreatic duct on MRCP.
of hemorrhage (Figure 5). Peripheral calciﬁcation is present
rarely. Cystic neuroendocrine tumors account for about 10%
of all pancreatic neuroendocrine tumors. They are highly
vascularized with early enhancement of the rim during
arterial imaging with MRI.
Cytologic evaluation of aspirated cyst ﬂuid from ﬁne
needle aspiration (FNA) is often performed during EUS but
at best has a sensitivity of 34% for mucinous lesions. Gly-
coprotein tumor antigens, such as carcinoembryonic antigen
(CEA), are secreted by epithelium lining mucinous lesions
and have been the focus of cyst ﬂuid analysis. A CEA level
>192ng/mL has modest sensitivity (75%) and speciﬁcity
(84%)formucinouscystic.However,manymucinouslesions
with CEA <192ng/mL are missed using this cutoﬀ.I n
addition, cyst ﬂuid CEA level is not predictive of malignancy.
Recent interest in DNA mutation analysis from cyst ﬂuid has
similarly proven disappointing. Measurement of allelic loss
amplitude has a sensitivity of 67% and speciﬁcity of 66% for
mucinous cystic lesions. The presence of a k-ras mutation
Figure 5: SPEN (arrow) with wall, internal septations and hemor-
rhage on MRI.
is highly speciﬁc (96%) for mucinous lesions but has a low
sensitivity of 45%.
4. DiagnosticEvaluationand Management
A diagnostic algorithm is proposed based on current data
and review of medical literature. Current treatment guide-
lines from several major gastrointestinal societies recom-
mend surgical resection for all deﬁnite MCNs and MD-
IPMN. Since premalignant MCNs typically occur in younger
women with a long life expectancy in the more easily
accessible pancreatic tail, and malignancy is detected in
about 70% of resected MD-IPMN specimens. Because the
occurrence of malignancy is much lower in BD-IPMN (15–
25% of patients), resection is reserved for those patients
with pancreatitis symptoms, main pancreatic duct dilation
>10mm, presence of mural nodules, cytology suspicious or
positive for malignancy, and/or possibly cysts >3cmpartic-
ularly in younger patients. Nonmucinous pancreatic lesions
(serous cystadenomas) do not require further evaluation.
The decision for surgical resection needs to be weighed
based on age, comorbidities, and resectability. A recent
Markov model incorporates these features to guide therapy.
Furthermore, a white paper from the radiology community
outlines an approach to asymptomatic cysts found on
abdominal imaging [28–35].
Accurate diagnosis of “indeterminate” pancreatic cystic
neoplasms is diﬃcult and often not possible until surgical
resection. For this reason we have developed an Interdis-
ciplinary Management of Pancreas Cystic Tumor (IMPACT)
Clinic that uses an initial triage algorithm that incorporates
the current literature. As can be seen from Table 2,i n
Step 1, clinical symptoms, laboratory data, and prior imag-
ing ﬁndings are collected and reviewed by an IMPACT
physician before the oﬃce visit. All patients must have a
pancreas protocol CT scan and/or MRI/MRCP to evaluate
the pancreas parenchyma and ductal anatomy. In Step 2,
oﬃce appointment triage is based on symptoms and deﬁnite
diagnosis of high risk lesions, as outlined. In essence, all
knownMD-IPMN,MCN,andsymptomaticlesionsregardless
of size are triaged initially for a surgical consultation to
determine operability and resectability.Gastroenterology Research and Practice 5
Table 2: Interdisciplinary management of pancreatic cystic tumors.
IMPACT Clinic Action points
Step 1
Collect outside data for IMPACT MD to
review before oﬃce visit
Initial review of outside medical records:
symptoms, laboratory, imaging review
with staﬀ radiologist
Consider repeat pancreas protocol CT
and MRI/MRCP to better visualize
pancreatic parenchyma and ductal
anatomy
Proceed to Step 2: arrange oﬃce visit and
imaging based on symptoms and imaging
Step 2
Initial triage based on symptoms or
ominous features on imaging:
Symptomatic or high risk lesion
Surgical referral (age, ASA grade,
resectability) may request EUS based on
ﬁndings
recurrent pancreatitis, dilated main duct,
mural nodule, solid component,
obstructive jaundice, abrupt caliber
change of duct
Asymptomatic Triage based on size
Proceed to Step 3
Step 3
Secondary triage based on cyst size
(i) IAP Guidelines, 2012
(ii) Am College of Radiology Guidelines,
2010
(iii) Markov model, 2010
(iv) Cost-eﬀective analysis, 2009
Cyst <1cm
Cyst 1–3cm
Cyst > 3cm
Medical pancreatology
Therapeutic endoscopy for EUS
Surgical referral (age, ASA grade,
resectability) may request EUS based on
ﬁndings
Proceed to Step 4 or 5b a s e do nr e s u l t so f
evaluation
Step 4
Clinical challenges
Indeterminate results:
equivocal imaging and/or cyst ﬂuid
analysis
Present case in weekly Multidisciplinary
Pancreas Study Group for consensus
recommendations
Proceed to Step 5
Step 5
IMPACT recommendations
Schedule follow-up appointment:
surgical resection, EUS –FNA, or
observation
Letter to referring MD and patient
Proceed to Step 6
Step 6
Followup
Surveillance recommendations based on
imaging, ﬂuid analysis, and/or surgical
pathology ﬁndings
IMPACT Clinical Database entry
Letter to referring MD and patient
Automated follow-up letter: 3 mo, 6 mo
etc...
Modiﬁed from Tanaka et al. [30], Berland [33], Khalid and Brugge [32], Das et al. [28], and Weinberg et al. [31].
In Step 3, asymptomatic lesions are triaged based on
size. Small, asymptomatic lesions <1cm in size, are initially
seen by a medical pancreatologist and followed based on
current IAP (International Association of Pancreatology)
and radiology society guidelines. Intermediate size lesions (1–
3cm in size) are initially seen by a therapeutic endoscopist
since EUS with cyst aspiration and analysis may be necessary
for further characterization. Large cystic lesions >3cm are
initially seen by a pancreatic surgeon for consideration of
surgical resection based on resectability and operability.
An intermediate Step 4 is suggested if initial evaluation
reveals indeterminate ﬁndings such as equivocal cyst ﬂuid
analysis, DNA markers, or borderline imaging features.
This step involves a formal case presentation to the weekly
Multidisciplinary Pancreas Study Group c o m p r i s e do fr a d i o l -
ogists,pancreaticobiliarysurgeons,therapeuticendoscopists,
medical pancreatologists, and gastroenterologists. The case
is presented by the IMPACT Clinic staﬀ at which time a
consensus opinion is given and later discussed with the
patient and referring physician.
Step 5 is a letter of communication from the IMPACT
Clinic outlining the treatment plan. Step 6i n v o l v e ss c h e d u l -
ingsurveillance,surgicalresection,orfurtherimaging.Final-
ly, patients are entered into a clinical database.
5. Conclusions
Pancreatic cystic neoplasms are increasingly recognized pri-
marilyduetotheincreaseduseandadvancementsofabdom-
inal imaging. Current methodologies including imaging,
endoscopy, and cyst ﬂuid analysis are imperfect in reliably
diﬀerentiating mucinous from nonmucinous pancreatic cys-
tic lesions and also cannot predict malignant transformation
with a high degree of accuracy. Strategies to manage this6 Gastroenterology Research and Practice
growing population of patients with potentially premalig-
nant pancreatic cystic lesions are greatly needed, both to
recognize lesions requiring aggressive surgical management,
to avoid unnecessary surgeries, and to appropriately utilize
diagnostic resources. Input from a variety of clinicians,
includinggastroenterologists,therapeuticendoscopists,radi-
ologists, pancreatic surgeons, and pathologists, is vital. An
interdisciplinary management algorithm is proposed that
stratiﬁes and triages patients based on symptoms, cyst size,
and deﬁnitive diagnosis.
6. FutureDirections
Better predictive biomarkers in cyst ﬂuid are greatly needed
and are under investigation. Recent data suggest that the
presence or absence of GNAS mutations may help diagnose
IPMN lesions. Gene expression proﬁling of pancreatic cyst
ﬂuid and confocal laser endomicroscopic examination of
pancreatic cysts are novel techniques also currently being
studied to better characterize lesions. In a recent meta-
analysis, expression of hTERT is strongly associated with
malignant transformation in IPMN, implicating upregula-
tion of hTERT as a key step in progression of IPMN to
cancer. Researchers are also using miRNA, proteomic and
cytokine proﬁling of cyst ﬂuid to discriminate among the
premalignant and benign neoplasms. EUS with ﬁne needle
injection of alcohol into the cyst (alcohol ablation) with or
without paclitaxel may be a viable option for cyst resolution
in nonoperative candidates [17, 36–43].
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